NDA Contender Plummets 5%... Nearly 1 Trillion Won Vanishes in U.S. Bio

BridgeBio Pharma Inc. (NASDAQ: BBIO) shares slid 5.18% to approximately $66.05 on the Nasdaq, marking a market correction. The company’s market capitalization is around $12.9 billion (about KRW 17.5 trillion), with roughly $640 million (about KRW 860 billion) erased in a single session. Trading volume reached about 2.13 million shares, indicating a wave of short-term profit-taking.

In its first-quarter results, BridgeBio reported revenue of $194.51 million and a net loss of $164.04 million. Supported by sales of its ATTR-CM therapy Atruvey, the company announced a share repurchase program of up to $500 million. Additionally, BridgeBio has submitted a New Drug Application (NDA) for BBP-418, its treatment for LGMD2I/R9, and on May 12 filed an FDA application for Encaleret, its rare-disease therapy for ADH1, underscoring its drive to commercialize its pipeline. (investor.bridgebio.com)

Headquartered in Palo Alto, California, BridgeBio Pharma is a commercial-stage biotech focused on genetic and rare diseases. Having already launched Atruvey for ATTR-CM, its late-stage pipeline includes BBP-418 for the rare muscle disorder LGMD2I/R9; Encaleret for ADH1 and chronic hypoparathyroidism; and inpigratinib for achondrogenesis and hypochondrogenesis, with multiple approvals and launches projected in 2026–2027. (investor.bridgebio.com)